# A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.

> **NCT05878691** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Glenmark Specialty S.A.** · enrollment: 320 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** GRC 54276
- **DRUG:** GRC 54276 + Pembrolizumab
- **DRUG:** GRC 54276 + Atezolizumab

## Key facts

- **NCT ID:** NCT05878691
- **Lead sponsor:** Glenmark Specialty S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-28
- **Primary completion:** 2027-07-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2024-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05878691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05878691, "A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05878691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*